Literature DB >> 81086

Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma.

P J Johnson, B Portmann, R Williams.   

Abstract

Serum alpha-fetoprotein (AFP) concentrations were estimated by sensitive radioimmunoassay in 30 patients with cirrhosis complicated by hepatocellular carcinoma and in 100 patients with cirrhosis in whom malignancy was excluded. Twenty-nine of the 30 patients with hepatocellular carcinoma had concentrations above 10 IU/ml (10.5 ng/ml) (median 3500 IU/ml (3675 ng/ml)), whereas only one of the 100 patients with cirrhosis and no tumour development had a raised concentration. Eleven out of 20 patients in whom hepatocellular carcinoma had developed in an apparently normal liver had raised AFP concentrations. In this group the differential diagnosis is usually secondary carcinoma, and three of 50 such patients had AFP concentrations above 10 IU/ml. Noting raised AFP concentrations is thus of considerable value both in detecting and in excluding hepatocellular carcinoma in cirrhosis, for in this case such concentrations gave only 1% false-positive and 3% false-negative results. They are less useful, however, in distinguishing between primary tumours arising in patients without cirrhosis and secondary hepatic deposits, giving 6% false-positive and 45% false-negative results.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 81086      PMCID: PMC1607440          DOI: 10.1136/bmj.2.6138.661

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  16 in total

1.  -Foetoprotein in normal human serum.

Authors:  E Ruoslahti; M Seppälä
Journal:  Nature       Date:  1972-01-21       Impact factor: 49.962

2.  Alpha-1-fetoprotein: serologic marker of human hepatoma and embryonal carcinoma.

Authors:  E Alpert
Journal:  Natl Cancer Inst Monogr       Date:  1972-12

3.  Serum-alpha 1-fetoprotein in hepatocellular carcinoma.

Authors:  J Kohn; P C Weaver
Journal:  Lancet       Date:  1974-08-10       Impact factor: 79.321

Review 4.  Alpha-fetoprotein in ontogenesis and its association with malignant tumors.

Authors:  G I Abelev
Journal:  Adv Cancer Res       Date:  1971       Impact factor: 6.242

5.  -fetoprotein in human hepatoma: improved detection in serum, and quantitative studies using a new sensitive technique.

Authors:  E Alpert; R Hershberg; P H Schur; K J Isselbacher
Journal:  Gastroenterology       Date:  1971-08       Impact factor: 22.682

6.  Influence of age on alpha-fetoprotein incidence.

Authors:  C Mawas; D Buffe; P Burtin
Journal:  Lancet       Date:  1970-06-13       Impact factor: 79.321

7.  Age-distribution of alpha-fetoprotein in hepatocellular carcinoma.

Authors:  A Bagshawe; A M Parker
Journal:  Lancet       Date:  1970-08-01       Impact factor: 79.321

8.  Methotrexate impurities.

Authors:  G Tisman; W A Winsten
Journal:  Lancet       Date:  1970-05-30       Impact factor: 79.321

9.  Serum alpha-fetoprotein: diagnostic significance in liver disease.

Authors:  E Ruoslahti; M Salaspuro; H Pihko; L Andersson; M Seppälä
Journal:  Br Med J       Date:  1974-06-08

10.  Serum alpha-feto-protein. VII. The range of apparent serum values in normal people, pregnant women, and primary liver cancer high risk populations.

Authors:  L R Purves; W R Branch; E W Geddes; C Manso; M Portugal
Journal:  Cancer       Date:  1973-03       Impact factor: 6.860

View more
  14 in total

Review 1.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis.

Authors:  A Maringhini; M Cottone; E Sciarrino; M P Marcenó; F La Seta; G Fusco; F Rinaldi; L Pagliaro
Journal:  Dig Dis Sci       Date:  1988-01       Impact factor: 3.199

Review 3.  Current concepts in rational therapy for haemochromatosis.

Authors:  D H Crawford; J W Halliday
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

4.  Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma.

Authors:  Terence C W Poon; Clarissa H S Chiu; Paul B S Lai; Tony S K Mok; Benny Zee; Anthony T C Chan; Joseph J Y Sung; Philip J Johnson
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

5.  Recent developments in the first detection of hepatocellular carcinoma.

Authors:  Joseph B Lopez
Journal:  Clin Biochem Rev       Date:  2005-08

6.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

7.  Hepatocellular carcinoma in HBsAg-negative chronic active hepatitis.

Authors:  P J Jenkins; W M Melia; B Portmann; J M Longworth Krafft; R Williams
Journal:  Gut       Date:  1981-04       Impact factor: 23.059

8.  Serum alpha-fetoprotein in patients following partial hepatectomy.

Authors:  N Nagasue; K Inokuchi; M Kobayashi; R Kanashima
Journal:  Dig Dis Sci       Date:  1980-04       Impact factor: 3.199

9.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

10.  Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma.

Authors:  P J Johnson; W M Melia; M K Palmer; B Portmann; R Williams
Journal:  Br J Cancer       Date:  1981-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.